February 19 2019

vasopharm GmbH obtains recommendation after interim review by the Data Monitoring Committee

“Continue the clinical trial with no modification up to 220 patients as planned.”

vasopharm GmbH, a privately held biopharmaceutical company, today announced that following a safety and efficacy interim assessment conducted according to the clinical trial protocol by the Data Monitoring Committee (DMC) it has received the following recommendation: “Continue the clinical trial with no modification up to 220 patients as planned.”

The company will follow DMC’s recommendation.

back